The regenerative capacity of viable cells remaining in cryopreserved vascular allografts is still unclear. Recently, the regenerating gene (Reg) has been documented to play an important role in various regenerating tissues. Here we show the possibility of Reg induction for the enhancement of cryopreserved vascular allograft viability. Cryopreserved rat aortae were isografted or allografted heterotopically. Fresh isografts were also tested. The transplants were retrieved 3, 6, 9, and 12 days after implantation and the intragraft Reg mRNA was measured by a real-time quantitative reverse transcriptional polymerase chain reaction method. Reg expression was not detected before implantation. Reg expression in cryopreserved isografts gradually increased after transplantation, whereas in fresh isografts or cryopreserved allografts it decreased over time after initial expression. Daily administration of 0.5 g/kg nicotinamide (an agent known to be a potent inducer of Reg) induced intragraft Reg mRNA in cryopreserved allografts (p < 0.05) accompanied by augmentation of the intragraft cell population. Daily administration of 0.5 mg/kg FK506 (an immunosuppressant) induced intragraft Reg mRNA both in cryopreserved isografts and allografts (p < 0.01). We conclude that Reg-inductive therapy shows promise as a novel strategy for enhancing the viability of vascular allografts. Moreover, FK506 may be involved in tissue regeneration as well as immunosuppression.

Keywords:
Regenerating gene, Vascular tissue, Cryopreservation, Transplantation, Allograft, Nicotinamide, FK506
1.
Vogt PR, von Segesser LK, Goffin Y, Niederhauser U, Genoni M, Kunzli A, Lachat M, Turina MI: Eradication of aortic infections with the use of cryopreserved arterial homografts. Ann Thorac Surg 1996;62:640–645.
2.
Mestres CA, Mulet J, Pomar JL: Large-caliber cryopreserved arterial allografts in vascular reconstructive operations: Early experience. Ann Thorac Surg 1995;60(suppl):S105–S107.
3.
Lund O, Chandrasekaran V, Grocott-Mason R, Elwidaa H, Mazhar R, Khaghani A, Mitchell A, Ilsley C, Yacoub MH: Primary aortic valve replacement with allografts over twenty-five years: Valve-related and procedure-related determinants of outcome. J Thorac Cardiovasc Surg 1999;117:77–90.
4.
Doty JR, Salazar JD, Liddicoat JR, Flores JH, Doty DB: Aortic valve replacement with cryopreserved aortic allograft: Ten-year experience. J Thorac Cardiovasc Surg 1998;115:371–379.
5.
O’Brien MF, Stafford EG, Gardner MA, Pohlner PG, McGiffin DC: A comparison of aortic valve replacement with viable cryopreserved and fresh allograft valves, with a note on chromosomal studies. J Thorac Cardiovasc Surg 1987;94:812–823.
6.
Song YC, Yao LY, Kneebone JM, Lupinetti FM: Effect of cryopreservation and histocompatibility on type I procollagen gene expression in aortic valve grafts. J Thorac Cardiovasc Surg 1997;114:421–427.
7.
Yonemura Y, Takashima T, Miwa K, Miyazaki I, Yamamoto H, Okamoto H: Amelioration of diabetes mellitus in partially depancreatized rats by poly(ADP-ribose) synthetase inhibitors. Evidence of islet B-cell regeneration. Diabetes 1984;33:401–404.
8.
Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino Y, Okamoto H: A novel gene activated in regenerating islets. J Biol Chem 1988;263:2111–2114.
9.
Akiyama T, Takasawa S, Nata K, Kobayashi S, Abe M, Shervani NJ, Ikeda T, Nakagawa K, Unno M, Matsuno S, Okamoto H: Activation of Reg gene, a gene for insulin-producing beta-cell regeneration: Poly(ADP-ribose) polymerase binds Reg promoter and regulates the transcription by autopoly(ADP-ribosyl)ation. Proc Natl Acad Sci USA 2001;98:48–53.
10.
Okamoto H: The Reg gene family and Reg proteins: With special attention to the regeneration of pancreatic beta-cells. J Hepatobiliary Pancreat Surg 1999;6:254–262.
11.
Fukui H, Kinoshita Y, Maekawa T, Okada A, Waki S, Hassan S, Okamoto H, Chiba T: Regenerating gene protein may mediate gastric mucosal proliferation induced by hypergastrinemia in rats. Gastroenterology 1998;115:1483–1493.
12.
Livesey FJ, O’Brien JA, Li M, Smith AG, Murphy LJ, Hunt SP: A Schwann cell mitogen accompanying regeneration of motor neurons. Nature 1997;390:614–618.
13.
Bustin SA: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169–193.
14.
Francavilla A, Starzl TE, Barone M, Zeng QH, Porter KA, Zeevi A, Markus PM, van den Brink MR, Todo S: Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. Hepatology 1991;14:140–143.
15.
Frizell E, Abraham A, Doolittle M, Bashey R, Kresina T, Van Thiel D, Zern MA: FK506 enhances fibrogenesis in in vitro and in vivo models of liver fibrosis in rats. Gastroenterology 1994;107:492–498.
16.
Tamura F, Masuhara A, Sakaida I, Fukumoto E, Nakamura T, Okita K: FK506 promotes liver regeneration by suppressing natural killer cell activity. J Gastroenterol Hepatol 1998;13:703–708.
17.
Navarro X, Udina E, Ceballos D, Gold BG: Effects of FK506 on nerve regeneration and reinnervation after graft or tube repair of long nerve gaps. Muscle Nerve 2001;24:905–915.
18.
Yoshikawa T, Nakajima H, Yamada E, Akahane M, Dohi Y, Ohgushi H, Tamai S, Ichijima K: In vivo osteogenic capability of cultured allogeneic bone in porous hydroxyapatite: Immunosuppressive and osteogenic potential of FK506 in vivo. J Bone Miner Res 2000;15:1147–1157.
19.
Akahane M, Ohgushi H, Yoshikawa T, Sempuku T, Tamai S, Tabata S, Dohi Y: Osteogenic phenotype expression of allogeneic rat marrow cells in porous hydroxyapatite ceramics. J Bone Miner Res 1999;14:561–568.
20.
Li J, Xu P, Chen H, Yang Z, Zhang Q: Improvement of tracheal autograft survival with transplantation into the greater omentum. Ann Thorac Surg 1995;60:1592–1596.
21.
Rouquier S, Verdier JM, Iovanna J, Dagorn JC, Giorgi D: Rat pancreatic stone protein messenger RNA. Abundant expression in mature exocrine cells, regulation by food content, and sequence identity with the endocrine reg transcript. J Biol Chem 1991;266:786–791.
22.
Gibson UE, Heid CA, Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995–1001.
23.
Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res 1996;6:986–994.
24.
Niwaya K, Sakaguchi H, Kawachi K, Kitamura S: Effect of warm ischemia and cryopreservation on cell viability of human allograft valves. Ann Thorac Surg 1995;60:S114–117.
25.
Kushibe K, Tojo T, Sakaguchi H, Takahama M, Nishizaki K, Nezu K, Taniguchi S: Effects of warm ischemia and cryopreservation on cartilage viability of tracheal allografts. Ann Thorac Surg 2000;70:1876–1879.
26.
Hirano T: Interleukin 6 and its receptor: Ten years later. Int Rev Immunol 1998;16:249–284.
27.
Oei FB, Stegmann AP, Vaessen LM, Marquet RL, Weimar W, Bogers AJ: Immunological aspects of fresh and cryopreserved aortic valve transplantation in rats. Ann Thorac Surg 2001;71:S379–384.
28.
Moustapha A, Ross DB, Bittira B, Van-Velzen D, McAlister VC, Lannon CL, Lee TD: Aortic valve grafts in the rat: Evidence for rejection. J Thorac Cardiovasc Surg 1997;114:891–902.
29.
Camargo CA Jr, Madden JF, Gao W, Selvan RS, Clavien PA: Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 1997;26:1513–1520.
30.
Debonera F, Aldeguer X, Shen X, Gelman AE, Gao F, Que X, Greenbaum LE, Furth EE, Taub R, Olthoff KM: Activation of interleukin-6/STAT3 and liver regeneration following transplantation. J Surg Res 2001;96:289–295.
31.
Yankah AC, Wottge HU, Muller-Ruchholtz W: Short-course cyclosporin A therapy for definite allograft valve survival immunosuppression in allograft valve operations. Ann Thorac Surg 1995;60(suppl):S146–S150.
32.
Azuma N, Sasajima T, Kubo Y: Immunosuppression with FK506 in rat arterial allografts: Fate of allogeneic endothelial cells. J Vasc Surg 1999;29:694–702.
33.
Messier RH Jr, Bass BL, Domkowski PW, Hopkins RA: Interstitial cellular and matrix restoration of cardiac valves after cryopreservation. J Thorac Cardiovasc Surg 1999;118:36–49.
34.
Dossche KM, de la Riviere AB, Morshuis WJ, Schepens MA, Defauw JJ, Ernst SM: Cryopreserved aortic allografts for aortic root reconstruction: A single institution’s experience. Ann Thorac Surg 1999;67:1617–1622.
35.
O’Brien MF, Harrocks S, Stafford EG, Gardner MA, Pohlner PG, Tesar PJ, Stephens F: The homograft aortic valve: A 29-year, 99.3% follow up of 1,022 valve replacements. J Heart Valve Dis 2001;10:334–344.
36.
Leseche G, Castier Y, Petit MD, Bertrand P, Kitzis M, Mussot S, Besnard M, Cerceau O: Long-term results of cryopreserved arterial allograft reconstruction in infected prosthetic grafts and mycotic aneurysms of the abdominal aorta. J Vasc Surg 2001;34:616–622.
37.
Vogt PR, Brunner-LaRocca HP, Lachat M, Ruef C, Turina MI: Technical details with the use of cryopreserved arterial allografts for aortic infection: Influence on early and midterm mortality. J Vasc Surg 2002;35:80–86.
38.
Mitchell RN, Jonas RA, Schoen FJ: Pathology of explanted cryopreserved allograft heart valves: Comparison with aortic valves from orthotopic heart transplants. J Thorac Cardiovasc Surg 1998;115:118–127.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.